GAMMA Investing LLC Acquires 42,177 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

GAMMA Investing LLC increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4,005.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,230 shares of the specialty pharmaceutical company's stock after purchasing an additional 42,177 shares during the quarter. GAMMA Investing LLC owned 0.08% of Supernus Pharmaceuticals worth $1,320,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after buying an additional 22,852 shares during the period. Geode Capital Management LLC lifted its holdings in Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock valued at $54,633,000 after acquiring an additional 28,517 shares during the period. American Century Companies Inc. boosted its position in Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock worth $27,242,000 after purchasing an additional 40,968 shares during the period. Finally, Northern Trust Corp raised its holdings in Supernus Pharmaceuticals by 18.3% in the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after purchasing an additional 110,867 shares during the period.

Analyst Ratings Changes

SUPN has been the subject of several recent research reports. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, May 16th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN traded up $0.63 during midday trading on Thursday, reaching $32.96. The stock had a trading volume of 583,113 shares, compared to its average volume of 485,204. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.55 and a 12-month high of $40.28. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 29.69 and a beta of 0.71. The stock has a 50-day moving average of $32.09 and a 200-day moving average of $34.27.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.